There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGO – Research Report), Avidity Biosciences (RNA – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments.
DocGo (DCGO)
Stifel Nicolaus analyst David Grossman maintained a Buy rating on DocGo today and set a price target of $6.50. The company’s shares closed last Thursday at $3.15, close to its 52-week low of $2.75.
According to TipRanks.com, Grossman is a 4-star analyst with an average return of
DocGo has an analyst consensus of Strong Buy, with a price target consensus of $6.30.
See Insiders’ Hot Stocks on TipRanks >>
Avidity Biosciences (RNA)
Avidity Biosciences received a Buy rating and a $56.00 price target from TD Cowen analyst Ritu Baral today. The company’s shares closed last Thursday at $47.05, close to its 52-week high of $49.41.
According to TipRanks.com, Baral is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avidity Biosciences with a $63.70 average price target, representing a 34.3% upside. In a report issued on September 24, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $59.00 price target.
Ultragenyx Pharmaceutical (RARE)
In a report released today, Dae Gon Ha from Stifel Nicolaus maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $127.00. The company’s shares closed last Thursday at $53.66.
According to TipRanks.com, Ha is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $84.80 average price target, which is a 53.6% upside from current levels. In a report issued on October 1, TD Cowen also maintained a Buy rating on the stock with a $61.00 price target.
Read More on DCGO:
